These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34703544)

  • 1. Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake
    Schueffl H; Theiner S; Hermann G; Mayr J; Fronik P; Groza D; van Schonhooven S; Galvez L; Sommerfeld NS; Schintlmeister A; Reipert S; Wagner M; Mader RM; Koellensperger G; Keppler BK; Berger W; Kowol CR; Legin A; Heffeter P
    Chem Sci; 2021 Oct; 12(38):12587-12599. PubMed ID: 34703544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity
    Mayr J; Heffeter P; Groza D; Galvez L; Koellensperger G; Roller A; Alte B; Haider M; Berger W; Kowol CR; Keppler BK
    Chem Sci; 2017 Mar; 8(3):2241-2250. PubMed ID: 28507680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs.
    Kastner A; Mendrina T; Bachmann F; Berger W; Keppler BK; Heffeter P; Kowol CR
    Inorg Chem Front; 2023 Jul; 10(14):4126-4138. PubMed ID: 37440920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents.
    Theiner S; Kornauth C; Varbanov HP; Galanski M; Van Schoonhoven S; Heffeter P; Berger W; Egger AE; Keppler BK
    Metallomics; 2015 Aug; 7(8):1256-64. PubMed ID: 25856224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance.
    Fronik P; Gutmann M; Vician P; Stojanovic M; Kastner A; Heffeter P; Pirker C; Keppler BK; Berger W; Kowol CR
    Commun Chem; 2022 Apr; 5(1):46. PubMed ID: 36697790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insertion of (Bioactive) Equatorial Ligands into Platinum(IV) Complexes.
    Kastner A; Schueffl H; Yassemipour PA; Keppler BK; Heffeter P; Kowol CR
    Angew Chem Int Ed Engl; 2023 Nov; 62(46):e202311468. PubMed ID: 37703130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of Light-Enhanced Extracellular Vesicle-Mediated Delivery of Oxaliplatin to Colorectal Cancer Cells via Laser Ablation, Inductively Coupled Plasma Mass Spectrometry.
    Chandler K; Millar J; Ward G; Boyall C; White T; Ready JD; Maani R; Chapple K; Tempest R; Brealey J; Duckett C; Haywood-Small S; Turega S; Peake N
    Cells; 2023 Dec; 13(1):. PubMed ID: 38201228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidney.
    Legin AA; Theiner S; Schintlmeister A; Reipert S; Heffeter P; Jakupec MA; Mayr J; Varbanov HP; Kowol CR; Galanski M; Berger W; Wagner M; Keppler BK
    Chem Sci; 2016 May; 7(5):3052-3061. PubMed ID: 29997796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents.
    Thiabaud G; He G; Sen S; Shelton KA; Baze WB; Segura L; Alaniz J; Munoz Macias R; Lyness G; Watts AB; Kim HM; Lee H; Cho MY; Hong KS; Finch R; Siddik ZH; Arambula JF; Sessler JL
    Proc Natl Acad Sci U S A; 2020 Mar; 117(13):7021-7029. PubMed ID: 32179677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs - an HPLC-ICP-MS study.
    Theiner S; Grabarics M; Galvez L; Varbanov HP; Sommerfeld NS; Galanski MS; Keppler BK; Koellensperger G
    Dalton Trans; 2018 Apr; 47(15):5252-5258. PubMed ID: 29560976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models.
    Göschl S; Schreiber-Brynzak E; Pichler V; Cseh K; Heffeter P; Jungwirth U; Jakupec MA; Berger W; Keppler BK
    Metallomics; 2017 Mar; 9(3):309-322. PubMed ID: 28205649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy.
    Tang L; Cai D; Qin M; Lu S; Hu MH; Ruan S; Jin G; Wang Z
    ACS Omega; 2020 Jan; 5(1):726-734. PubMed ID: 31956823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conjugation of oxaliplatin with PEGylated-nanobody for enhancing tumor targeting and prolonging circulation.
    Li L; Zhu Y; Liu M; Jin D; Zhang L; Cheng J; Liu Y
    J Inorg Biochem; 2021 Oct; 223():111553. PubMed ID: 34340059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albumin in vivo rats and in vitro study using inductively coupled plasma-mass spectrometory.
    Kato R; Sato T; Iwamoto A; Yamazaki T; Nakashiro S; Yoshikai S; Fujimoto A; Imano H; Ijiri Y; Mino Y; Chikuma M; Tanaka K; Hayashi T
    Biopharm Drug Dispos; 2019 Jul; 40(7):242-249. PubMed ID: 31219617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.
    Burz C; Berindan-Neagoe IB; Balacescu O; Tanaselia C; Ursu M; Gog A; Vlase L; Chintoanu M; Balacescu L; Leucuta SE; Irimie A; Cristea V
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):39-43. PubMed ID: 19337632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nano-scale imaging of dual stable isotope labeled oxaliplatin in human colon cancer cells reveals the nucleolus as a putative node for therapeutic effect.
    Legin AA; Schintlmeister A; Sommerfeld NS; Eckhard M; Theiner S; Reipert S; Strohhofer D; Jakupec MA; Galanski MS; Wagner M; Keppler BK
    Nanoscale Adv; 2021 Jan; 3(1):249-262. PubMed ID: 36131874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of oxaliplatin: a critical review.
    Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
    Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
    Lévi F; Metzger G; Massari C; Milano G
    Clin Pharmacokinet; 2000 Jan; 38(1):1-21. PubMed ID: 10668856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of Subcellular Distribution of Platinum in Single Cells Using Laser Ablation Inductively Coupled Plasma Mass Spectrometry.
    Managh AJ; Greenhalgh CJ
    Methods Mol Biol; 2024; 2752():215-226. PubMed ID: 38194037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Pt(IV) prodrug self-assembled nanoparticles with enhanced blood circulation stability and improved antitumor capacity of oxaliplatin for cancer therapy.
    Fu Y; Kong Y; Li X; Cheng D; Hou Y; Li Y; Li T; Xiao Y; Zhang Q; Rong R
    Drug Deliv; 2023 Dec; 30(1):2171158. PubMed ID: 36744299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.